Skip to main content
. 2011 Apr 26;152(7):2722–2730. doi: 10.1210/en.2010-1464

Fig. 2.

Fig. 2.

Dopaminergic regulation of pituitary TGF-β1. A, The effect of dopaminergic drugs at short time (30 min) on pituitary active TGF-β1 content was measured in Drd2+/+ mice. Cabergoline (2 mg/kg BW, ip) or sulpiride (5 mg/kg BW, ip) was injected, and 30 min later, animals were killed. Cabergoline did not modify active TGF-β1 content, whereas sulpiride induced a decrease in pituitary active TGF-β1. *, P = 0.0031 control vs. sulpiride, (n = 12, 7, and 5). B, Serum PRL levels were assayed by RIA as a control of dopaminergic drug effects. Cabergoline inhibition and sulpiride stimulation of PRL levels were observed. *, P = 0.0007; #, P = 0.0001 vs. control. (n = 13, 15, and 18). C, A 24-h treatment with dopaminergic drugs did not affect total pituitary TGF-β1 (n = 10, 6, and 6). D, TGF-β1 mRNA levels were not modified by dopaminergic drugs after a 24-h treatment (n = 8, 5, and 5). E, Dopaminergic drug effects on serum PRL levels after a 24-h treatment. Cabergoline inhibitory effect on serum PRL was observed. *, P = 0.017 cabergoline vs. control. No effect of sulpiride was found at this time (n = 20, 16, and 22). All data were analyzed by one-way ANOVA and Fisher's protected least significant difference post hoc test.